Study: Chocolate Eclairs for the treatment of prostate cancer?

Veröffentlicht: 01. August 2023, 22:27 Uhr

Von: Natur.wiki Autoren-Team

Die Studie untersucht die Auswirkungen einer polyaminreduzierten Diät (PRD) bei Patienten mit hormonrefraktärem Prostatakrebs (HRPC). In der Studie wurden 42 Patienten aufgenommen, von denen 26 eine polyaminreduzierte Diät einhielten. Die Parameter, die gemessen wurden, waren der Leistungsstatus der Patienten, die Schmerzskala, das Körpergewicht, das Blutbild und die Serumproteine. Die Ergebnisse zeigten, dass die Diät gut vertragen wurde und zu Verbesserungen sowohl im Leistungsstatus als auch bei den Schmerzen führte. Die krebsspezifische Überlebenszeit war signifikant länger bei Patienten, die frühzeitig mit der Diät begonnen hatten. Die Ergebnisse legen nahe, dass eine polyaminreduzierte Diät einen positiven Nutzen für Patienten mit hormonrefraktärem Prostatakrebs … — The study examines the effects of a polyamin -reduced diet (PRD) in patients with hormone refractory prostate cancer (HRPC). In the study, 42 patients were admitted, 26 of whom kept a polyamin -reduced diet. The parameters that were measured were the patient's performance status, pain scale, body weight, blood count and serum proteins. The results showed that the diet was well tolerated and led to improvements both in the performance status and the pain. The cancer -specific survival time was significantly longer in patients who had started the diet early. The results suggest that a polyamin -reduced diet is a positive benefit for patients with hormone refractory prostate cancer ... (Symbolbild/natur.wiki)

The study examines the effects of a polyamin -reduced diet (PRD) in patients with hormone -refractory prostate cancer (HRPC). In the study, 42 patients were admitted, 26 of whom kept a polyamin -reduced diet. The parameters that were measured were the patient's performance status, pain scale, body weight, blood count and serum proteins. The results showed that the diet was well tolerated and led to improvements both in the performance status and the pain. The cancer -specific survival time was significantly longer in patients who had started the diet early. The results suggest that a polyamin -reduced diet can have a positive benefit for patients with hormone -refractory prostate cancer.

Details of the study:

Reference

CIPOLLA BG, Havouis R, Moulinoux JP. Nutritional therapy with polyamin -reduced diet (PRD) in patients with hormone -refractory prostate cancer. biomed pharmacother . 2010; 64 (5): 363-368.

Design

42 voluntary patients with hormone refractory prostate cancer (HRPC) were included in the study. The intervention group (n = 26) adhered to a polyamin -reduced diet. They were also subjected to a partial intestinal contamination, in which they were given either neomycin or nifuroxazide every two weeks. The remaining 16 participants neither ate a special diet nor did they take antimicrobial medication. The measured parameters include the performance status of the World Health Organization (WHO), the pain scale of the European Organization for Research and Treatment of Cancer (Eortc), body weight, blood count and serum proteins.

most important knowledge

The diet was well tolerated and the average compliance was 25 (± 24) months. The performance status and the pain improved significantly after 3 months (p = 0.03) and after 6 months (p = 0.02) compared to the initial value. It is noteworthy that the intervention in this study was significantly better if it was carried out within 9 months after the diagnosis of a hormone refractory status. The average cancer-specific survival for patients who start with the diet before the 9-month limit is 44 months, compared to 34 months for those who later begin (p = 0.014). The middle cancer -specific survival times for the intervention groups in total compared to the control groups are 36 months compared to 17 months (p = 0.004).

effects on practice

HRPC is defined by the ineffectiveness of testosterone reduction by castration or antiandrogenic drugs when checking prostate cancer growth. The forecast for these patients is bad because HRPC does not respond well to chemotherapeutic agents. The latest reports on survival data can be obtained from clinical studies for the newly approved antineoplastic agent Sipulucel-T (Provenge®). This immune-modulating therapy received FDA approval in April 2010, based on the increase in the increase in average overall survival time from HRPC patients from about 21 months to 25 months.

Polyamines (e.g. Putrecin, spermidine, sperm) increase cell proliferation and occur in cancer cells, including prostate cancer, in higher concentration. ^{2 There are three sources for polyamines: 1) Natural occurrence in food and drinks, 2) Production of intra -groove and 3) Intracellular synthesis of Polyamines. In the early 1990s, studies in rodents showed that triple treatment with a diet without polyamines, an intestinal contamination with antimicrobial means and taking a drug that blocks the first enzyme in its synthesis (e.g. ornithine hindecarboxylase) to a significantly reduced tumor growth led. 3 The authors of the current summary published a large part of the early work on cancer models on rodents, which repeatedly showed effective tumor inhibition through polyamin deficiency by targeting all three sources of the connections.}

In this study, the dietary intervention was to divide food and drinks into three groups. Group 1 were foods with less than 100 NMOL/G/ML that could be consumed freely. Group 2 were foods with 101–200 NMOL/G/ML, which could be taken 3–4 times a week. Group 3 had a polyamin concentration of more than 201 NMOL/G/ML and was prohibited every 7 days.

This nutritional protocol differs significantly from what we mean by good nutrition. First of all, we assume that the intestinal flora is advantageous; We would rarely encourage you to take antibiotics specifically to eradicate them. Second, food is dispensed with, which we would otherwise classify as very nutritious. Group 3 includes, for example, garlic, cabbage, broccoli, tomatoes, almonds, bananas, mushrooms and sauerkraut. Conversely, group 1, i.e. the category that could be consumed freely, comprised pork products, vegetable soup in cans, dairy products (except matured cheese), beer, coffee and sponge cake. The French authors belong to chocolate reclairs to the group of foods that can be consumed freely. This diet deviates significantly from everything we have routinely recommended to our patients.

The list contains much more food and there is no recognizable way to memorize the food. Therefore, a grocery list must be used to adhere to the diet.

While one would assume that it could be difficult for patients to stick to restrictive food groups without an obvious context, compliance with the diet in this study was extremely high.

While one would assume that it could be difficult for patients to stick to restrictive food groups without an obvious context, compliance with the diet in this study was extremely high. Of course, the permission of the unlimited absorption of foods that are considered to be enjoyable according to most nutritional standards that explain the good compliance by the participants.

Intervention in this study aimed at the polyamine pool produced by intestinal microbes and included a partially "intestinal contamination" with neomycin or nifuroxazide, which consisted of a daily oral dose of antimicrobial agent that was taken every two weeks. The intestinal flora, which has been proven to produce polyamines, include: Klebsiella pneumonia , Enterobacter spp. And Serratia spp. 9 The fact that antimicrobial means were an essential part of the therapy of these patients reminds us that the basics of general health, in this case a healthy microflora, should not be rejected as too weak or too fundamental in order to have profound effects on cancer treatment. Based on our understanding of the growth suppression of probiotics, it can be expected that probiotics would reduce polyamine synthesis in the intestine by checking bacterial growth. In fact, studies with certain probiotics have shown a reduction in polyamines.

Ultimately, the examination of the intestinal flora can be displayed in our patients with HRPC, since many of the above organisms are found in a thorough microbial stool test. Natural antimicrobial means can also be used and the patient tested again to assess the success of the treatment. The prudent use of antimicrobial active ingredients is out of the question in patients with HRPC in view of the serious forecast and the relative risk-benefit ratio of the medication.

This study is small and only includes 42 participants. Nevertheless, the results achieved statistical significance, which can only be achieved if the benefit in small studies is quite large. The dietary intervention does not cause any disadvantage because a reduction in polyamin consumption does not lead to nutrient deficits. Therefore, the risk-benefit ratio of the dietary intervention is certainly favorable, especially in view of the poor prognosis of patients with HRPC. It is noteworthy that this special study was carried out in France, where the ethnic differences in food selection make it difficult to derive the various food groups that were administered to these patients. In addition, there was no objective measurement of polyamin status, such as: B. urine or chair values that could help to estimate the value from which a benefit arises.

In addition to the early rodent studies, which confirmed the effectiveness of the polyamin reduction, Cipolla and colleagues published a pilot study with 13 volunteers with HRPC. ¹¹ In this previous study, pain and performance status improved during the dietary intervention However, back after stopping the diet. The prostate -specific antigen (PSA) was also determined. In a patient there was a reduction by> 50 %, in three patients <50 % and the PSA was increasingly deteriorating in all others. The dietary intervention was significantly shorter, with the average compliance with the diet after 8 (± 7) months. The cancer -specific survival time was 14 (± 7) months, which is also much shorter than in the current study, but may be due to the termination of the diet by the participants. In addition, the patients started in this previous study with dietary intervention at a later date after their initial HRPC diagnosis (12 (± 8) months) than in the current study (10 (± 8) months). The current study suggests that the beginning of a dietary intervention brings significantly less use at a later date. Clinically, it can be assumed that the use of a diet with a low polyaming content "does not do any damage" and can actually bring significant benefits for patients with HRPC. Probiotics also have an extremely favorable side effect profile and should be considered as part of every treatment protocol for HRPC patients. A further examination of the intestinal flora and the treatment of dysbiotic bacteria should also be considered. The use of medication that blocks polyamine synthesis is increasingly gaining interest, and future studies could lead their use and dosage for selected types of cancer. While drug development continues to inhibit polyamine synthesis, it seems that we can help our patients today with nutrition and intestinal health, especially our patients with HRPC.

For further research on integrative oncology, click here Here .